First‐line epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor alone or with whole‐brain radiotherapy for brain metastases in patients with EGFR‐mutated lung adenocarcinoma

We proposed to compare the outcomes of first‐line epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR‐TKI) alone with EGFR‐TKI plus whole‐brain radiotherapy (WBRT) for the treatment of brain metastases (BM) in patients with EGFR‐mutated lung adenocarcinoma. A total of 1665 patients were...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yongshun, Yang, Jing, Li, Xue, Hao, Daxuan, Wu, Xiaoyuan, Yang, Yuanyuan, He, Chunyu, Wang, Wen, Wang, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198957/
https://www.ncbi.nlm.nih.gov/pubmed/27627582
http://dx.doi.org/10.1111/cas.13079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198957/
https://www.ncbi.nlm.nih.gov/pubmed/27627582
http://dx.doi.org/10.1111/cas.13079

Ejemplares similares